The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Primary analysis of a randomized phase II, multicenter trial: Neoadjuvant weekly nab-paclitaxel 100mg/m2 followed by FE100C compared with docetaxel 75mg/m2 followed by FE100C for early breast cancer in Japan.
 
Takashi Kuwayama
Honoraria - Chugai Pharma; Eisai; Taiho Pharmaceutical
 
Hideko Yamauchi
Honoraria - Daiichi Sankyo; Devicor Medical Products; Eisai; FALCO biosystems; Genomic Health; Nihon Medi-Physics; Novartis; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda
 
Toshimi Takano
Honoraria - AstraZeneca; Eisai; Kyowa Hakko Kirin; Taiho Pharmaceutical
 
Koichiro Tsugawa
No Relationships to Disclose
 
Takanobu Sato
No Relationships to Disclose
 
Akira Kitani
No Relationships to Disclose
 
Naoki Hayashi
Honoraria - Chugai Pharma; Eisai; Genomic Health; Novartis; Sanofi; Taiho Pharmaceutical; Takeda
 
Hiromi Okuyama
No Relationships to Disclose
 
Seigo Nakamura
No Relationships to Disclose